Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
- Conditions
- Coronavirus InfectionsSARS (Severe Acute Respiratory Syndrome)Coronavirus Sars-AssociatedCOVID-19
- Interventions
- Biological: Marine liquid and fluidsBiological: ImpregnationBiological: IncubationBiological: ManipulationBiological: Refrigeration
- Registration Number
- NCT05054075
- Lead Sponsor
- Universidade do Porto
- Brief Summary
The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.
- Detailed Description
A deep and consistent study will be developed with an increase in the human sampling for better understanding the intervention efficacy of this intelligence medicine integrator, the Mora® Nova method. These in silico experiments when associated with the bioresonance frequencies from stimulated hemolymph compounds of the freshwater bivalve A. cygnea, may lead us to expect high plasticity and immunological potential.
Obviously, additional in vitro studies in future, with adequate culture cell lineages in different conditions and with bioresonance treatment by Mora® Nova method, should also be accomplished with hemolymph/plasma interference to confirm the pertinence, and the real efficacy on SARS / COVID-19 infection as well as to clarify the respective biological mechanisms.
In addition, to analyze and evaluate any specific bioactive compound from the induced hemolymph condition needs molecular experiments which can give deep structural information concerning any efficient molecule against the SARS / COVID-19 virus lineage and respective mutants. Effectively, according to current scientific opinion, the virus mutation phenomenon leads to great and problematic difficulty for maintaining the collective and human global immunization. In this case, the present Mora methodology offers a very functional, dynamic, and efficient process when combined with a biological model, as the bivalve A. cygnea, with high plasticity and eventual molecular reconstructive adaptation. This Mora procedure can extend to other immune-depressive diseases namely cancer, rheumatoid arthritis, and neurodegenerative diseases combining with respective stimulated bivalve fluids. It suggests opening a promising future perspective when applied to large human sampling as well as with in vitro cellular assays.
In addition, to explore this research with in vitro cell cultures and to do the characterization and the effects from bio-compounds on similar diseases is our close objective.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 45
- Subjects with normal physiological state or any kind of comorbidity
- Subjects in highly critical health state
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Vaccinated Incubation Subjects that received a vaccine against COVID-19 lineage virus Non-vaccinated Incubation Subjects that did not receive a vaccine against COVID-19 lineage virus Vaccinated Marine liquid and fluids Subjects that received a vaccine against COVID-19 lineage virus Infected Impregnation Subjects that are infected with a COVID-19 lineage virus Vaccinated Impregnation Subjects that received a vaccine against COVID-19 lineage virus Vaccinated Manipulation Subjects that received a vaccine against COVID-19 lineage virus Non-vaccinated Impregnation Subjects that did not receive a vaccine against COVID-19 lineage virus Non-vaccinated Refrigeration Subjects that did not receive a vaccine against COVID-19 lineage virus Vaccinated Refrigeration Subjects that received a vaccine against COVID-19 lineage virus Non-vaccinated Marine liquid and fluids Subjects that did not receive a vaccine against COVID-19 lineage virus Non-vaccinated Manipulation Subjects that did not receive a vaccine against COVID-19 lineage virus Infected Incubation Subjects that are infected with a COVID-19 lineage virus Infected Manipulation Subjects that are infected with a COVID-19 lineage virus Infected Marine liquid and fluids Subjects that are infected with a COVID-19 lineage virus Infected Refrigeration Subjects that are infected with a COVID-19 lineage virus
- Primary Outcome Measures
Name Time Method Immunologic system change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints
Pulmonary system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints
Pulmonary system change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints
Cardiac system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints
Cardiac system change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints
Immunologic system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints
- Secondary Outcome Measures
Name Time Method Nervous system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on nervous system biopoints
Gastrointestinal system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints
Gastrointestinal system Change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints
Nervous system change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on nervous system biopoints
Endocrine system T0 - Day 1 - Baseline Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints
Endocrine system change T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints
Trial Locations
- Locations (2)
ICBAS - University of Porto
🇵🇹Porto, Portugal
Instituto Politécnico de Bragança
🇵🇹Bragança, Portugal